Notes d’épisode
AVIR stock analysis: Atea targets 846% upside — buy or sell biotech deep dive
👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends
In this deep dive, we break down Atea Pharmaceuticals, Inc. (AVIR) and its potential to disrupt standard-of-care oral antivirals with its lead Phase 3 combination regimen. With shares trading around $4.21, an enterprise value of approximately $227.5M, and a funded operational runway extending into mid-2028, the key question…
Site web: flash.stocksentinel.ai

